TCG Labs

Managing Partner of TCG Labs and Chief Executive Officer of TCG Labs Soleil, leading the firm's venture-biotech model.

Principal at TCG Labs; formerly a VP at Samsara BioCapital leading life sciences investments and previously biology lead at Halda Therapeutics. Holds a PhD from Yale and a PharmD from Butler University.

VP, Clinical Development and Translational Medicine at Soleil Labs (Shanghai) with experience across China, the US and Europe. Earned his MD from China Pharmaceutical University and PhD at UCLA.

Board-certified rheumatologist and immunologist with over four decades of experience across academia and industry, including senior roles at Nektar Therapeutics and Amgen. Serves on several biotech boards.

Scientific Partner; HHMI Investigator and inaugural Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering. Founder of ORIC Pharmaceuticals.

Scientific Partner; professor at Columbia University Medical Center and HHMI investigator known for sensory neuroscience and taste research. Co-founder of Kallyope.

Associate at TCG Labs; previously Head of Search and Evaluation at Autobahn Labs and co-founder/CSO of Beeline Therapeutics. Earned his PhD from UCSF.

Scientific Partner; founding Chair of the Department of Molecular Biology at UT Southwestern, known for cardiac and muscle developmental biology and CRISPR approaches to Duchenne muscular dystrophy. Co-founder of Exonics Therapeutics.

Scientific Partner; human geneticist and HHMI investigator at UT Southwestern, known for discoveries in lipid metabolism and PCSK9. Member of the National Academy of Sciences.

Chief Medical Officer at Soleil with over 21 years leading clinical development, previously CMO/EVP at NGMbio and VP of Early Clinical Development at Genentech. Received his MD from Albert Einstein.

Scientific Partner; professor at Baylor College of Medicine, HHMI investigator and director of the Duncan Neurological Research Institute, known for genetics of Rett syndrome and SCA1.

Joined TCG Labs Soleil in January 2026 with over 25 years leading clinical development operations, previously SVP at Alector and earlier roles at Genentech, Ultragenyx, Biogen and Merck.

SVP of Translational Science with over two decades in drug discovery, previously SVP and Head of Discovery and Early Development at Brii Biosciences and 18 years at Tularik/Amgen.

VP, Head of Clinical Operations at Soleil Labs (Shanghai) with over ten years leading complex oncology programs, previously at LianBio and local biopharma. Holds a master's in pharmacy from Guangdong Pharmaceutical University.

SVP of External Innovations and General Manager at Soleil Labs (Shanghai) with nearly three decades of pharma/biotech leadership, previously SVP of Preclinical Sciences at Haihe Biopharma. Earned his PhD from Rice University.

SVP, Head of Development at Soleil Labs (Shanghai) with nearly 20 years of clinical research experience, previously SVP Global Head of Development at LianBio. Received his Doctor of Engineering at Fudan University.

Chief Development Officer at Soleil with over 30 years of drug development experience across biotech and pharma including Brii Biosciences, GSK, Merck and Johnson & Johnson.

VP of Clinical Development, Oncology at Soleil with extensive experience developing biologics for cancer, previously Executive Medical Director at Asher Biotherapeutics. Earned his MD and PhD at Cambridge.

VP of Clinical Development, Immunology at Soleil with over 30 years in clinical practice, research and drug development, having contributed to several NDA/BLA and MAA approvals. Holds an MD and PhD from Japanese universities.

VP, Clinical Strategy and Operations at Soleil Labs (Shanghai), previously Director of Biology and Pipeline Assets Planning at LianBio. Earned his PhD from the Chinese Academy of Sciences.

Scientific Partner; former chief scientific officer at 23andMe and EVP/head of research and early development at Genentech. Awarded the 2013 Lasker Basic Medical Research Award and 2010 Kavli Prize.

Discovery Partner and founding Science Partner of TCG; former President of the Howard Hughes Medical Institute and discoverer of the first human transcription factors. Co-founder of Tularik.

Scientific Partner; President, CEO and Board Chair of Eikon Therapeutics and former EVP of Merck and head of Merck Research Laboratories.

Analyst at TCG Labs; previously on the Asset Selection team at RTW Investments and worked in public equities at Oppenheimer & Co. Completed his PhD at Cornell University and the Sloan Kettering Institute.

Scientific Partner; VP and Staff Scientist of Physiological Chemistry at Genentech, known for pioneering work on apoptosis. Member of the National Academy of Sciences.

VP, Head of Medicinal Chemistry at Soleil Labs (Shanghai) with over fifteen years in small-molecule drug discovery, previously Head of Medicinal Chemistry at Haihe Biopharma. Earned his PhD in organic chemistry from the University of Pittsburgh.